AstraZeneca discontinues eVOLVE-Lung02 Phase 3 trial for futility
AZN is discontinuing the eVOLVE-Lung02 Phase 3 trial after the IDMC concluded it was unlikely to meet either dual primary endpoint.
Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
1 result loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
AZN is discontinuing the eVOLVE-Lung02 Phase 3 trial after the IDMC concluded it was unlikely to meet either dual primary endpoint.